Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 5, 2003, Pages 913-921

  Szczeklik, Andrew ^a   Stevenson, Donald D ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Aspirin desensitization; Aspirin induced asthma; Chronic sinusitis; COX 1 and 2 inhibitors; Nasal polyposis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; AZAPROPAZONE; BENZYDAMINE; CELECOXIB; CHLOROQUINE; CHOLINE MAGNESIUM TRISALICYLATE; CORTICOSTEROID; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYSTEINYLLEUKOTRIENE RECEPTOR; DEXTROPROPOXYPHENE; ICOSANOID; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MELOXICAM; MONTELUKAST; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRANLUKAST; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SALICYLAMIDE; SALICYLATE SODIUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGY TEST; ASPIRIN INDUCED ASTHMA; ASTHMA; BRONCHOSPASM; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DESENSITIZATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; HUMAN; MOLECULAR BIOLOGY; NOSE POLYP; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; RECURRENT DISEASE; REVIEW; RHINOSINUSITIS; SYNDROME; SYSTEMIC THERAPY;

EID: 0038405018     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1487     Document Type: Review

References (102)

1. Widal MF, Abrani P, Lermoyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922;30:189-92.
2. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Int Med 1968;68:975-83.
3. Szczeklik A., Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
4. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177-80.
5. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22.
6. Kasper Ł, Sładek K, Duplaga M, Bochenek G, Liebhard J, Gładysz U, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. In press 2003.
7. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin-intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002;57:569-74.
8. Szczeklik A, Niżankowska E, Duplaga M, on behalf ofthe AIANE investigators: Natural history of aspirin-induced asthma. Eur Respir J 2000;16:432-6.
9. Bochenek G, Niżankowska E, Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996;51:16-23.
10. Kalyoncu AF, Karakaya G, Sahin AA, Baris YI. Occurrence of allergic conditions in asthmatic with analgesic intolerance. Allergy 1999;54:428-35.
11. Pastorello EA, Zara C, Riario-Sforza GG, Pravettoni V, Incorvaia C. Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 1998;53:880-4.
12. Berges-Gimeno, MP, Simon, RA Stevenson DD. The natural history and clinical characteristics of aspirin exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:472-8.
13. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy: principles and practice. St. Louis: Mosby; 1998. p. 1225-34.
14. Setkowicz M, Zembowicz A, Mastalerz L, Szczeklik A. NSAIDs sensitivity in chronic idiopathic urticaria: selective involvement of cyclooxygenase-1 and overproduction of cysteinyl-leukotrienes. J Allergy Clin Immunol. In press 2003.
15. Szczeklik A, Niżankowska E, Mastalerz L, Bochenek G. Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol 2002;109:572-3.
16. Bochenek G, Niżankowska E, Szczeklik A. Testing for aspirin hypersensitivity. Allergy 2002;57:562-5.
17. Niżankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863-9.
18. Bianco S, Robuschi M, Petrigni G. Aspirin-induced tolerance in aspirin-induced asthma detected by a new challenge technique. IRCS J Med Sci 1977;5:129-30.
19. Melillo G, Balzano G, Bianco S, Dahlen B, Godard Ph, Kowalski ML, et al. Report of the INTERASMA Working Group on standardization of inhalation provocation tests in aspirin-induced asthma. Allergy 2001;56:899-911.
20. Milewski M, Mastalerz L, Niżankowska E, Szczeklik A. Nasal provocation test for diagnosis of aspirin-induced asthma. J Allergy Clin Immunol 1998;101:581-6.
21. Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002;57:632-5.
22. Nasser SM, Lee TH. Leukotrienes in aspirin-sensitive asthma. In: Szczeklik A, Gryglewski RJ, Vane J, editors. Eicosanoids, aspirin and asthma. New York: Marcel Dekker; 1998. p. 317-36.
23. 4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999;103:559-64.
24. De Weck AL, Stadler BH, Urwyler A, Wechner HU, Bühlmann RP, et al. Cellular antigen stimulation test (CAST): a new dimension in allergy diagnosis. Allergy Clin Immunol News 1993;5:9-14.
25. May A, Weber A, Gall H, Kaufmann R, Zollner TM. Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance. Clin Exp Allergy 1999;29:1402-11.
26. Schäfer D, Schmid M, Gode UC, Baenkler HW. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999;13:638-46.
27. Pierzchalska M, Mastalerz L, Sanak M, Zazula M, Szczeklik A. A moderate and unspecific release of cysteinyl-leukotrienes by aspirin from peripheral blood leukocytes precludes its value for aspirin-sensitivity testing in asthma. Clin Exp Allergy 2000;30:1785-91.
28. Gray PA, Warner TD, Vojnovic I, Del Soldato P, Parikh A, Scadding GK, et al. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors. Br J Pharmacol 2002;137:1031-8.
29. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67-9.
30. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990;3:588-93.
31. Szczeklik A, Sanak M. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 2002;32:339-42.
32. Chandrasekharan NV, Hu Dai, Lamar Turepu Roos K, Evanson NK, Tomsik J, Elton TS, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31.
33. Bazan NG, Flower RJ. Lipid signals in pain control. Nature 2002.420:136-8.
34. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa A, Amaysu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000;106:1201-2.
35. Szczeklik A, Niżankowska E, Bochenek G, Nagraba K, Mejza F, Świerczyńska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219-25.
36. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. N Engl J Med 2001;344:142.
37. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
38. Szczeklik A, Gryglewski RJ, Olszewski E, Debińska-Kieć A, Czerniawska-Mysik G. Aspirin-sensitive asthma: the effect of aspirin on the release of prostaglandin from nasal polyps. Pharmacol Res Commun 1977;9:415-25.
39. Picado C, Fernandez-Morata JC, Juan M, Roca-Ferrer J, Fuentes M, Xaube A, et al. Cyclooxygenase-2 mRNA is down-expressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Cell Mol Biol 2000;160:291-6.
40. Kowalski ML, Pawliczak R, Woźniak J, Sluda M, Poniatowska J, Iwaszkiewicz T, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391-8.
41. Mullol J, Fernandez-Morata JC, Roca-Ferrer J, Pujols L, Xaubet A. Benitez P, et al. Cyclooxygenase 1 and cyclooxygenase 2 expression in abnormally regulated in human nasal polyps. J Allergy Clin Immunol 2002;109:824-30.
42. 2 and aspirin-induced asthma. Lancet 1995;345:1056.
43. 2. Lancet 1995;345:436-8.
44. 2 in airways of subjects with asthma. Am J Respir Crit Care Med 2000;162:637-40.
45. 2 and CAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy. Am J Respir Cell Mol Biol 2001;24:44-8.
46. 2 production by bronchial fibroblasts of asthmatic patients with special reference to aspirin-iaduced asthma. J Allergy Clin Immunol 2003;111:1041-8.
47. Antczak A, Montuschi P, Kharitonow S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002;166:301-6.
48. Obase Y, Shimoda T, Tomari S, Mitsuta K, Kawano T, Matsuse H, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002;121:143-50.
49. 4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-46.
50. Szczeklik A, Sładek K, Dworski R, Niżankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes speeific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-14.
51. Sanak M, Sampson AP. Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999;29:306-13.
52. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000;23:290-6.
53. 4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002;109:936-42.
54. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600.
55. 4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000;106:72-6.
56. 4 synthase polymorphism and aspirin-induced asthma. J Allergy Clin Immunol 2001;107:561.
57. 4 synthase gene expression in the monocyte-like cell line. THP-1. Am J Respir Crit Care Med 2000;23:234-40.
58. 4 synthase involves a Kruppel-like transcription factor and Sp1. J Biol Chem 2000;275:8903-10.
59. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate S, Holloway JW, et al. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000;55:S28-S31.
60. Lynch KR, O'Neill GP, Liu Q, Im D-S, Sawyer N, Metters KM, et al. Characterisation of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999;399:789-93.
61. Arm JP, Austen KF. Leukotriene receptors and aspirin sensitivity. N Engl J Med 2002;347:1524-6.
62. Takasaki J, Kamohara M, Matsumoto M, Saito T, Sugimoto T, Oshishi T, et al. The molecular characterisation and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000;274:316-22.
63. Sousa AR, Parkih A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-9.
64. Sanak M, Levy BD, Clish CB, Chiang N, Gronert K, Mastalerz L, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000;16:44-9.
65. Chavis C, Vachier J, Godard P, Bousquet J, Chanez P. Lipoxins and other arachidonate-derived mediators in bronchial asthma. Thorax 2000;55(suppl 2):S38-S41.
66. Nasser MS, Lee TH. Products of 15-lipoxygenase: are they important in asthma? Clin Exp Allergy 2002;32:1540-2.
67. Levy BD, De Sanctis GT, Devhand PR, Kim E, Ackerman K, Schmidt BA, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nature Med 2002;8:1018-23.
68. 2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996;98:421-32.
69. Mita H, Endoh S, Kudoh M, Kawagishi Y, Kabayashi M, Taniguchi M, et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001;56:1061-7.
70. 2 metabolite) in plasma and urine of patients with bronchaial asthma and healthy controls following the aspirin challenge. J Allergy Clin Immunol. In press 2003.
71. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.
72. Zhu H, Cong J-P, Yu D, Bresnahan WA, Shenk TE. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci U S A 2002;99:3932-7.
73. 4 excretion in aspirin-induced asthma. J Allergy Clin Immunol 1998;102:909-14.
74. Okada H, Ohnishi T, Hirashima M, Fujita J, Yamaji Y, Takahara J, et al. Anti-asthma effect of an antiviral drug, acyclovir: a clinical case and experimental study. Clin Exp Allergy 1997;27:431-7.
75. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal antiinflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977;60:276-84.
76. Settipane RA, Stevenson DD. Cross-sensitivity with acetaminophen in aspirin sensitive subjects with asthma. J Allergy Clin Immunol 1989;84:26-33.
77. Tattersfield AE, Knox AJ, Britton JR, Hall IP, Asthma. Lancet 2002,360:1313-22.
78. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976;57:440-8.
79. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980;66:82-8.
80. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zieger RS. Aspirin desensitization in aspirin sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982;69:11-9.
81. Stevenson DD. Drug-induced asthma. In: Slavin R, Reisman RE, editors. Asthma. Vol. 1. Philadelphia: American College of Physicians: 2002. p. 191-208.
82. Berges-Gimeno M, Simon RA, Stevenson DD. Treatment with aspirin desensitization in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180-6.
83. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production following aspirin desensitization. J Allergy Clin Immunol 1995;96:148-56.
84. Nasser SMS, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentration in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995;151:1326-30.
85. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956-9.
86. Perez-G M, Melo, M, Keegan, AD, Zamorano, J. Aspirin and salicylates inhibit the IL-4 and IL-13 induced activation of STAT6. J Immunol 2002;168:1428-34.
87. Dahlen B, Niżankowska E, Szczeklik A, Zetterstrom O, Bochenek G, Kumlin M, et al. Benefits from adding the 5-lipooxygenase inhibitor Zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Cate Med 1998;157:1187-94.
88. Dahlen S-E, Malmstrom K, Niżankowska E, Dahlen B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. A randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9-14.
89. Yoshida S, Sakamoto H, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, et al. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000;30:64-70.
90. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000;85:477-82.
91. Enrique E, Garcia-Ortega P, Gaig P, San Miguel MM. Failure of montelukast to prevent anaphylaxis to diclofenac. Allergy 1999;54:529-30.
92. Szczeklik A, Mastalerz L, Niżankowska E, Sanak M. Montelukast for persistent asthma. Lancet 2001;358:1456-7.
93. Mastalerz L, Niżankowska E, Sanak M, Mejza F, Pierzchalska M, Bazan-Socha S, et al. Clinical anal genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002;32:949-95.
94. Mastalerz L, Gawlewicz-Mroczka A, Niżankowska E, Emiel A, Szczeklik A. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002;32:1360-5.
95. Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001;31:1385-91.
96. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene polymorphism and clinical response to a cys-LTs antagonist, pranlukast. Pharmacogenetics 2002;12:565-70.
97. Szczeklik A, Mastalerz L, Niżankowska É, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Cate Med 1996;153:567-71.
98. 4 excretion in aspirin-sensitive asthma. Am J Respir Crit Cate Med 1996;153:572-5.
99. Wasiak W, Szmidt M. A six-week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma. Thorax 1999;54:900-4.
100. Shoji T, Yoshida S., Sakamoto H, Hasegawa H, Nakagawa H, Amaysu H, et al. Anti-inflammatory effect of roxitromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999;29:950-6.
101. Mastalerz L, Milewski M, Duplaga M, Niżankowska E, Szczeklik A. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy 1997;52:895-900.
102. Hesemann W. Surgical treatment of nasal polyposis in patients with aspirin intolerance. Thorax 2000;55:S87-S90.